Literature DB >> 15078968

Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia.

Soile Blomqvist1, Carita Savolainen, Pia Laine, Päivi Hirttiö, Elisa Lamminsalo, Eija Penttilä, Silver Jöks, Merja Roivainen, Tapani Hovi.   

Abstract

Two types of vaccine-derived polioviruses have been recently designated to emphasize the different origins of the evolved viruses: circulating vaccine-derived polioviruses (cVDPV) associated with outbreaks of paralytic disease and strains isolated from chronically infected immunodeficient individuals (iVDPV). We describe here a type 3 VDPV (PV3/EST/02/E252; later E252) isolated from sewage collected in Tallinn, Estonia, in October 2002. Due to aberrant properties in subtyping, the virus was subjected to detailed characterization. Partial genomic sequencing suggested that the closest relative was the oral vaccine strain PV3/Sabin, but the two virus strains shared only 86.7% of the 900 nucleotides (nt) coding for the capsid protein VP1. Phylogenetic analysis of the nearly complete genome [nt 19 to poly(A)] revealed multiple nucleotide substitutions throughout the genome and a possible Sabin 3/Sabin 1-recombination junction site in the 2C coding region. A calculation based on the estimated mutation frequency of the P1 region of polioviruses suggested that the E252 virus might have replicated in one or more individuals for approximately 10 years. No persons chronically excreting poliovirus are known in Estonia. Amino acid substitutions were seen in all known antigenic sites, which was consistent with the observed aberrant antigenic properties of the virus demonstrated by both monoclonal antibodies and human sera from vaccinated children. In spite of the apparent transmission potential, no evidence was obtained for circulation of the virus in the Estonian population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15078968      PMCID: PMC387693          DOI: 10.1128/jvi.78.9.4876-4883.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion.

Authors:  J Martín; G Dunn; R Hull; V Patel; P D Minor
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Antigenic structure of polioviruses of serotypes 1, 2 and 3.

Authors:  P D Minor; M Ferguson; D M Evans; J W Almond; J P Icenogle
Journal:  J Gen Virol       Date:  1986-07       Impact factor: 3.891

3.  RASMOL: biomolecular graphics for all.

Authors:  R A Sayle; E J Milner-White
Journal:  Trends Biochem Sci       Date:  1995-09       Impact factor: 13.807

4.  Comparative study of five methods for intratypic differentiation of polioviruses.

Authors:  H G van der Avoort; B P Hull; T Hovi; M A Pallansch; O M Kew; R Crainic; D J Wood; M N Mulders; A M van Loon
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

5.  Characterisation of L cells expressing the human poliovirus receptor for the specific detection of polioviruses in vitro.

Authors:  P A Pipkin; D J Wood; V R Racaniello; P D Minor
Journal:  J Virol Methods       Date:  1993-03       Impact factor: 2.014

6.  Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: assessment of intestinal immunity with live challenge virus.

Authors:  L Piirainen; M Stenvik; M Roivainen; J Eskola; E C Beuvery; T Hovi
Journal:  Vaccine       Date:  1999-03-05       Impact factor: 3.641

7.  Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient.

Authors:  O M Kew; R W Sutter; B K Nottay; M J McDonough; D R Prevots; L Quick; M A Pallansch
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

8.  High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; F Delpeyroux; M Tardy-Panit; J Balanant; M Combiescu; A A Combiescu; S Guillot; R Crainic
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination.

Authors:  K S Lole; R C Bollinger; R S Paranjape; D Gadkari; S S Kulkarni; N G Novak; R Ingersoll; H W Sheppard; S C Ray
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  Tripartite genome organization of a natural type 2 vaccine/nonvaccine recombinant poliovirus.

Authors:  M M Georgescu; F Delpeyroux; R Crainic
Journal:  J Gen Virol       Date:  1995-09       Impact factor: 3.891

View more
  35 in total

1.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

2.  Isolation and detection of enterovirus RNA from large-volume water samples by using the NucliSens miniMAG system and real-time nucleic acid sequence-based amplification.

Authors:  Saskia A Rutjes; Ronald Italiaander; Harold H J L van den Berg; Willemijn J Lodder; Ana Maria de Roda Husman
Journal:  Appl Environ Microbiol       Date:  2005-07       Impact factor: 4.792

3.  Use of a multiple restriction fragment length polymorphism method for detecting vaccine-derived polioviruses in clinical samples.

Authors:  Natalia I Romanenkova; Sophie Guillot; Nadejda R Rozaeva; Radu Crainic; Maina A Bichurina; Francis Delpeyroux
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

4.  Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine.

Authors:  E A Cherkasova; M L Yakovenko; G V Rezapkin; E A Korotkova; O E Ivanova; T P Eremeeva; L I Krasnoproshina; N I Romanenkova; N R Rozaeva; L Sirota; V I Agol; K M Chumakov
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Retrospective characterization of a vaccine-derived poliovirus type 1 isolate from sewage in Greece.

Authors:  Evaggelos Dedepsidis; Zaharoula Kyriakopoulou; Vaia Pliaka; Christine Kottaridi; Eugenia Bolanaki; Stamatina Levidiotou-Stefanou; Dimitri Komiotis; Panayotis Markoulatos
Journal:  Appl Environ Microbiol       Date:  2007-09-07       Impact factor: 4.792

6.  Vaccine derived bi- and multi-recombinant Sabin strains.

Authors:  Eleni Paximadi; Ioannis Karakasiliotis; Eugenia Bolanaki; Aris Krikelis; Panayotis Markoulatos
Journal:  Virus Genes       Date:  2007-08-07       Impact factor: 2.332

7.  Highly divergent type 2 and 3 vaccine-derived polioviruses isolated from sewage in Tallinn, Estonia.

Authors:  Haider Al-Hello; Jaume Jorba; Soile Blomqvist; Riina Raud; Olen Kew; Merja Roivainen
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

8.  Molecular identification and full genome analysis of an echovirus 7 strain isolated from the environment in Greece.

Authors:  Zaharoula Kyriakopoulou; Evaggelos Dedepsidis; Vaia Pliaka; Panayotis Mastorakos; Anastassia Stamati; Anastassia Pratti; Stamatina Levidiotou-Stefanou; Panayotis Markoulatos
Journal:  Virus Genes       Date:  2010-01-22       Impact factor: 2.332

9.  Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum.

Authors:  Minetaro Arita; Masae Iwai; Takaji Wakita; Hiroyuki Shimizu
Journal:  Clin Vaccine Immunol       Date:  2011-08-31

10.  Feasibility of quantitative environmental surveillance in poliovirus eradication strategies.

Authors:  W J Lodder; A M Buisman; S A Rutjes; J C Heijne; P F Teunis; A M de Roda Husman
Journal:  Appl Environ Microbiol       Date:  2012-03-23       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.